Trials / Completed
CompletedNCT03341884
A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Ipatasertib in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase 1 study evaluating the pharmacokinetics, tolerability and safety of a single dose of ipatasertib in participants with mild, moderate or severe hepatic impairment compared to healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ipatasertib | A single oral dose of 100 mg ipatasertib will be administered. |
Timeline
- Start date
- 2017-11-09
- Primary completion
- 2018-06-26
- Completion
- 2018-06-26
- First posted
- 2017-11-14
- Last updated
- 2019-11-18
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03341884. Inclusion in this directory is not an endorsement.